Zacks: Cynapsus Therapeutics Inc. (CYNA) Given $36.50 Consensus Price Target by Brokerages
Cynapsus Therapeutics Inc. (NASDAQ:CYNA) has earned a consensus broker rating score of 1.50 (Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and three have given a strong buy rating to the company. Cynapsus Therapeutics’ rating score has declined by 50% from 90 days ago as a result of various analysts’ ratings changes.
Brokers have set a one year consensus price target of $36.50 for the company and are predicting that the company will post ($0.75) earnings per share for the current quarter, according to Zacks. Zacks has also given Cynapsus Therapeutics an industry rank of 99 out of 265 based on the ratings given to its competitors.
Several brokerages have issued reports on CYNA. Janney Montgomery Scott cut shares of Cynapsus Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, September 1st. BMO Capital Markets set a $30.00 price target on shares of Cynapsus Therapeutics and gave the company a “buy” rating in a research report on Tuesday, August 16th. Finally, Noble Financial reiterated a “buy” rating and set a $50.00 price objective on shares of Cynapsus Therapeutics in a research report on Tuesday, August 30th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/19/zacks-cynapsus-therapeutics-inc-cyna-given-36-50-consensus-price-target-by-brokerages.html
An institutional investor recently bought a new position in Cynapsus Therapeutics stock. Havens Advisors LLC acquired a new stake in Cynapsus Therapeutics Inc. (NASDAQ:CYNA) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 47,500 shares of the company’s stock, valued at approximately $1,911,000. Cynapsus Therapeutics comprises about 1.5% of Havens Advisors LLC’s investment portfolio, making the stock its 19th largest position. Havens Advisors LLC owned approximately 0.38% of Cynapsus Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 56.62% of the company’s stock.
Shares of Cynapsus Therapeutics (NASDAQ:CYNA) traded up 0.02% during midday trading on Wednesday, reaching $40.48. 32,011 shares of the company’s stock traded hands. The company has a 50 day moving average of $38.95 and a 200 day moving average of $20.97. The firm’s market cap is $502.40 million. Cynapsus Therapeutics has a 52-week low of $10.54 and a 52-week high of $40.67.
Cynapsus Therapeutics (NASDAQ:CYNA) last announced its quarterly earnings results on Thursday, August 11th. The company reported $0.83 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.77) by $1.60. On average, equities analysts predict that Cynapsus Therapeutics will post ($3.15) EPS for the current fiscal year.
Cynapsus Therapeutics Company Profile
Cynapsus Therapeutics Inc is a Canada-based specialty central nervous system (CNS) pharmaceutical company. It develops a sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD). The Company completed a Phase two clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cynapsus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynapsus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.